Press Releases

Check back often to find the latest news on AgeneBio and our pipeline of multiple candidates.

September 11, 2019

AgeneBio Announces Additional Funding to Advance Novel GABA-A Therapeutic Program to Address Alzheimer’s and Other CNS Conditions

AgeneBio today announced it has received significant additional resources to accelerate the development of their GABA-A a5 Positive Allosteric Modulation (PAM), a novel approach to mild cognitive impairment (MCI) due to Alzheimer's Disease (AD) that targets hippocampal overactivity that leads to degeneration and cognitive decline in patients with MCI due to AD, autism and schizophrenia.

May 2, 2019

T.J. Oshie and Dr. Michela Gallagher Honored at Ninth Annual Great Ladies Luncheon

Dr. Michela Gallagher, founder and CEO of AgeneBio, Inc. and professor at Johns Hopkins University, was honored at the luncheon for her work advancing treatments for Alzheimer's disease. Dr. Gallagher received the inaugural Estelle Gelman Award for Innovation in Drug Discovery for her groundbreaking research that holds the potential to yield the first drug to slow the progression of symptoms associated with mild cognitive impairment due to Alzheimer's disease.

April 30, 2018

AgeneBio Founder Dr. Michela Gallagher participates in the 2018 Milken Global Conference

Gallagher highlights the groundbreaking clinical trial, HOPE4MCI, which could slow progression from Mild Cognitive Impairment to Alzheimer’s dementia LOS ANGELES, April 30, 2018 — Today, AgeneBio Founder Dr. Michela Gallagher participated in a panel discussion at the Milken Global Conference Alzheimer’s Disease: Rewriting the Playbook.…

February 28, 2018

AgeneBio to Speak at ASENT 2018 Annual Meeting

Emerging Therapeutics Focus on Hippocampal Hyperactivity in Patients with Mild Cognitive Impairment Due to Alzheimer’s Disease Baltimore, MD, February 28, 2018 — AgeneBio, a pharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced that founder and Chief…

February 28, 2018

AgeneBio Founder Michela Gallagher to Speak at 2018 NIH Alzheimer’s Research Summit

Focus on Research Targeting Hippocampal Hyperactivity in Patients with Mild Cognitive Impairment Due to Alzheimer’s Disease Baltimore, MD, February 28, 2018 — AgeneBio, a pharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced that founder and Chief…